替格瑞洛药物利用评价标准的构建和应用

张瑜; 郑宓; 章婧; 张进华; 曾茂贵

引用本文:	张瑜,郑宓,章婧,张进华,曾茂贵.替格瑞洛药物利用评价标准的构建和应用[J].中国现代应用药学,2024,41(10):.
	zhangyu,zhengmi,zhangjing,zhangjinhua,zengmaogui.Establishment and Application of Drug Use Evaluation Standard of Ticagrelor[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(10):.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 106次下载 112次
分享到：微信更多字体:加大+\|默认\|缩小-
替格瑞洛药物利用评价标准的构建和应用
张瑜¹, 郑宓¹, 章婧², 张进华³, 曾茂贵¹
1.福建中医药大学附属第二人民医院;2.福建中医药大学人民医院;3.福建省妇幼保健院

摘要:

目的建立替格瑞洛药物利用评价(drug use evaluation,DUE)标准,为临床合理应用替格瑞洛提供参考。方法以替格瑞洛说明书为基础,参考相关指南、专家共识和文献,并通过专家咨询法,从用药指征、用药过程和用药结果3个方面建立替格瑞洛的DUE标准。采用回顾性研究法,对某三甲医院2021年1月—12月使用替格瑞洛的病历进行合理用药评价。结果建立的替格瑞洛DUE标准分为三级,包括一级指标3项,二级指标14项,三级指标60项。共纳入使用替格瑞洛的病例263例,其中不合理率为72.62%,不合理情况主要为超适应证用药(60.08%)、药物转换(14.83%)和用法用量(5.70%)等方面。结论建立的替格瑞洛DUE标准有较强的科学性、实用性和可行性,可为临床合理用药和处方点评提供参考依据。

关键词: 关键词替格瑞洛药物利用评价专家咨询法

DOI：

分类号:

基金项目:

Establishment and Application of Drug Use Evaluation Standard of Ticagrelor

zhangyu¹, zhengmi¹, zhangjing², zhangjinhua³, zengmaogui¹

1.The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine;2.the Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine;3.Fujian Maternity and Child Health Hospital

Abstract:

ABSTRACT: OBJECTIVE To establish the drug use evaluation(DUE) standard of ticagrelor, and to provide a reference for the rational clinical application of ticagrelor. METHODS Based on the ticagrelor drug label, related guidelines and literature, combined with clinical expert consultation results, DUE standard from three levels (indications, medications and medication results) was established. A retrospective survey was conducted to evaluate the inpatients using ticagrelor from January 2021 to December 2021 in the Author's hospital. RESULTS The DUE of ticagrelor was divided into three levels, including 3 first-level indexes,14 second-level indexes and 60 third-level indexes. A total of 263 cases of using ticagrelor were included, A total of 263 cases using ticagrelor were included, of which the irrational rate was 72.62%. The irrational cases were mainly off-label use (60.08%), inappropriate drug conversion (14.83%) and unreasonable usage and dosage (5.70%). CONCLUSION The established DUE standard of ticagrelor is scientific, practical and feasible, which can provide reference for clinical rational drug use and prescription evaluation.

Key words: ticagrelor drug use evaluation expert consultation